Healthcare companies by risk reading
Healthcare companies by risk reading: 1,695 companies ranked by a composite risk reading built from filed statements -- leverage, cash conversion, operating pressure, customer and supplier concentration and competitive position. Recomputed 21 October 2026.
Composite readings for 14,899 companies, recomputed 21 October 2026. A company appears here once at least three weighted categories cleared their inputs; the rest carry per-mechanism readings without a headline.
| Company | Reading | Band | Sector | Country | Coverage | Market cap |
|---|---|---|---|---|---|---|
| Teladoc Health Inc TDOC | 72 | Stretched | Healthcare | United States | 5 / 6 | $1.0B |
| Maravai LifeSciences Holdings Inc - Class A MRVI | 70 | Stretched | Healthcare | United States | 5 / 6 | $1.0B |
| Ryman Healthcare Limited RYM.AX | 74 | Stretched | Healthcare | New Zealand | 4 / 6 | $1.0B |
| Harrow Inc HROW | 31 | Normal | Healthcare | United States | 6 / 6 | $1.0B |
| Lumexa Imaging Holdings Inc LMRI | 57 | Elevated | Healthcare | United States | 4 / 6 | $1.0B |
| Janux Therapeutics Inc JANX | 66 | Stretched | Healthcare | United States | 5 / 6 | $1.0B |
| CStone Pharmaceuticals 2616.HK | 64 | Stretched | Healthcare | China | 4 / 6 | $1.0B |
| SSY Group Limited 2005.HK | 54 | Elevated | Healthcare | Hong Kong | 5 / 6 | $1.0B |
| Xunfei Healthcare Technology Co., Ltd. 2506.HK | 48 | Elevated | Healthcare | China | 5 / 6 | $1.0B |
| Kissei Pharmaceutical Co., Ltd. 4547.T | 49 | Elevated | Healthcare | Japan | 5 / 6 | $1.0B |
| PHILOGEN PHIL.MI | 14 | Contained | Healthcare | Italy | 5 / 6 | $995M |
| Ceribell Inc CBLL | 53 | Elevated | Healthcare | United States | 5 / 6 | $994M |
| Clinica Baviera CBAV | 24 | Normal | Healthcare | Spain | 3 / 6 | $985M |
| Summerset Group Holdings Ltd SNZ | 50 | Elevated | Healthcare | New Zealand | 4 / 6 | $983M |
| Basilea Pharmaceutica AG BSLN | 23 | Normal | Healthcare | Switzerland | 5 / 6 | $982M |
| Castle Biosciences Inc CSTL | 47 | Elevated | Healthcare | United States | 5 / 6 | $981M |
| Healthstream Inc HSTM | 48 | Elevated | Healthcare | United States | 4 / 6 | $974M |
| Thomson Medical Group Limited A50.SI | 53 | Elevated | Healthcare | Singapore | 5 / 6 | $972M |
| Mani, Inc. 7730.T | 28 | Normal | Healthcare | Japan | 5 / 6 | $967M |
| Ryman Healthcare Limited RH70 | 72 | Stretched | Healthcare | New Zealand | 4 / 6 | $966M |
| Oncolys BioPharma Inc. 4588.T | 83 | Acute | Healthcare | Japan | 5 / 6 | $964M |
| Immatics N.V IMTX | 75 | Stretched | Healthcare | Germany | 5 / 6 | $964M |
| Vetoquinol VETO | 42 | Elevated | Healthcare | France | 5 / 6 | $960M |
| Mannkind Corp MNKD | 40 | Elevated | Healthcare | United States | 4 / 6 | $958M |
| CanSino Biologics Inc. 6185.HK | 41 | Elevated | Healthcare | China | 5 / 6 | $954M |
| VYNE Therapeutics Inc VYNE | 39 | Normal | Healthcare | United States | 4 / 6 | $953M |
| Regis Healthcare Limited REG.AX | 31 | Normal | Healthcare | Australia | 4 / 6 | $951M |
| Silence Therapeutics Plc SLN | 75 | Stretched | Healthcare | United Kingdom | 6 / 6 | $925M |
| Kaken Pharmaceutical Co., Ltd. 4521.T | 57 | Elevated | Healthcare | Japan | 5 / 6 | $921M |
| Bioventus Inc - Class A BVS | 39 | Normal | Healthcare | United States | 5 / 6 | $920M |
| BML, Inc. 4694.T | 42 | Elevated | Healthcare | Japan | 5 / 6 | $909M |
| Monte Rosa Therapeutics Inc GLUE | 48 | Elevated | Healthcare | United States | 5 / 6 | $909M |
| Modern Dental Group Limited 3600.HK | 25 | Normal | Healthcare | Hong Kong | 5 / 6 | $899M |
| Medincell SA MEDCL | 52 | Elevated | Healthcare | France | 5 / 6 | $894M |
| Menicon Co., Ltd. 7780.T | 43 | Elevated | Healthcare | Japan | 5 / 6 | $892M |
| BML Inc BMZ | 44 | Elevated | Healthcare | Japan | 5 / 6 | $891M |
| MeiraGTx Holdings plc MGTX | 50 | Elevated | Healthcare | United States | 5 / 6 | $890M |
| JINS HOLDINGS Inc. 3046.T | 30 | Normal | Healthcare | Japan | 5 / 6 | $889M |
| Theravance Biopharma Inc TBPH | 43 | Elevated | Healthcare | United States | 6 / 6 | $884M |
| Oxford BioMedica PLC OXB | 65 | Stretched | Healthcare | United Kingdom | 6 / 6 | $879M |
| SI-BONE Inc SIBN | 55 | Elevated | Healthcare | United States | 6 / 6 | $879M |
| Rigel Pharmaceuticals RIGL | 29 | Normal | Healthcare | United States | 6 / 6 | $872M |
| QuidelOrtho Corporation QDEL | 61 | Stretched | Healthcare | United States | 5 / 6 | $872M |
| PeptiDream Inc. 4587.T | 79 | Stretched | Healthcare | Japan | 5 / 6 | $871M |
| Talkspace Inc TALK | 41 | Elevated | Healthcare | United States | 4 / 6 | $871M |
| Kuros Biosciences AG KURN | 33 | Normal | Healthcare | Switzerland | 5 / 6 | $869M |
| Luye Pharma Group Ltd. 2186.HK | 46 | Elevated | Healthcare | China | 5 / 6 | $868M |
| Odyssey Therapeutics, Inc. ODTX | 68 | Stretched | Healthcare | United States | 5 / 6 | $867M |
| Alphamab Oncology 9966.HK | 51 | Elevated | Healthcare | China | 5 / 6 | $850M |
| CARsgen Therapeutics Holdings Limited 2171.HK | 53 | Elevated | Healthcare | China | 5 / 6 | $847M |
| Zylox-Tonbridge Medical Technology Co., Ltd. 2190.HK | 21 | Normal | Healthcare | China | 5 / 6 | $845M |
| Arbutus Biopharma Corp ABUS | 64 | Stretched | Healthcare | United States | 4 / 6 | $836M |
| Aktis Oncology Inc AKTS | 71 | Stretched | Healthcare | United States | 5 / 6 | $836M |
| Kura Oncology Inc KURA | 67 | Stretched | Healthcare | United States | 5 / 6 | $833M |
| Sihuan Pharmaceutical Holdings Group Ltd. 0460.HK | 43 | Elevated | Healthcare | Hong Kong | 5 / 6 | $819M |
| Esperion Therapeutics Inc ESPR | 38 | Normal | Healthcare | United States | 4 / 6 | $819M |
| Alumis Inc ALMS | 62 | Stretched | Healthcare | United States | 4 / 6 | $815M |
| Advanced Medical Solutions Group plc AMS.L | 28 | Normal | Healthcare | United Kingdom | 5 / 6 | $814M |
| Lepu Biopharma Co., Ltd. 2157.HK | 27 | Normal | Healthcare | China | 5 / 6 | $809M |
| Inmode Ltd INMD | 47 | Elevated | Healthcare | Israel | 5 / 6 | $809M |
| AdaptHealth Corp AHCO | 50 | Elevated | Healthcare | United States | 6 / 6 | $801M |
| SAFILO GROUP SFL.MI | 43 | Elevated | Healthcare | Italy | 5 / 6 | $800M |
| Dynavox Group DYVOX | 32 | Normal | Healthcare | Sweden | 4 / 6 | $800M |
| LifeTech Scientific Corporation 1302.HK | 44 | Elevated | Healthcare | China | 5 / 6 | $793M |
| MedCap MCAP.ST | 18 | Contained | Healthcare | Sweden | 3 / 6 | $787M |
| DocMorris AG DOCM | 73 | Stretched | Healthcare | Switzerland | 5 / 6 | $782M |
| Ascletis Pharma Inc. 1672.HK | 66 | Stretched | Healthcare | Hong Kong | 5 / 6 | $782M |
| Verastem Inc VSTM | 41 | Elevated | Healthcare | United States | 5 / 6 | $780M |
| Alebund Pharmaceuticals (Jiangsu) Limited 9637.HK | 61 | Stretched | Healthcare | China | 5 / 6 | $776M |
| Varex Imaging Corp VREX | 47 | Elevated | Healthcare | United States | 5 / 6 | $776M |
| Paul Hartmann AG PHH2.F | 44 | Elevated | Healthcare | Germany | 5 / 6 | $775M |
| Geron Corp GERN | 65 | Stretched | Healthcare | United States | 4 / 6 | $771M |
| Ardelyx Inc ARDX | 65 | Stretched | Healthcare | United States | 6 / 6 | $770M |
| Arjo AB (publ) ARJO-B | 45 | Elevated | Healthcare | Sweden | 4 / 6 | $769M |
| Beta Bionics Inc BBNX | 40 | Elevated | Healthcare | United States | 6 / 6 | $757M |
| Collegium Pharmaceutical Inc COLL | 33 | Normal | Healthcare | United States | 6 / 6 | $748M |
| Synsam AB SYNSAM | 36 | Normal | Healthcare | Sweden | 5 / 6 | $738M |
| Gubra A/S GUBRA | 18 | Contained | Healthcare | Denmark | 5 / 6 | $736M |
| Mochida Pharmaceutical Co., Ltd. 4534.T | 44 | Elevated | Healthcare | Japan | 5 / 6 | $727M |
| Nxera Pharma Co., Ltd. 4565.T | 65 | Stretched | Healthcare | Japan | 5 / 6 | $721M |
| Hygeia Healthcare Holdings Co., Limited 6078.HK | 41 | Elevated | Healthcare | China | 5 / 6 | $720M |
| China Shineway Pharmaceutical Group Limited 2877.HK | 38 | Normal | Healthcare | China | 5 / 6 | $716M |
| China Shineway Pharmaceutical Group Limited C1S | 40 | Elevated | Healthcare | China | 5 / 6 | $716M |
| Gushengtang Holdings Limited 2273.HK | 20 | Normal | Healthcare | China | 5 / 6 | $713M |
| Abbisko Cayman Limited 2256.HK | 21 | Normal | Healthcare | China | 5 / 6 | $708M |
| Enhabit Inc EHAB | 51 | Elevated | Healthcare | United States | 5 / 6 | $707M |
| Jinxin Fertility Group Limited 1951.HK | 63 | Stretched | Healthcare | China | 5 / 6 | $704M |
| Phreesia Inc PHR | 31 | Normal | Healthcare | United States | 6 / 6 | $700M |
| Pharming Group NV PHARM | 30 | Normal | Healthcare | Netherlands | 4 / 6 | $694M |
| Japan Lifeline Co., Ltd. 7575.T | 38 | Normal | Healthcare | Japan | 5 / 6 | $694M |
| Prime Medicine Inc PRME | 57 | Elevated | Healthcare | United States | 5 / 6 | $692M |
| Sosei Group Corporation JSS | 64 | Stretched | Healthcare | Japan | 5 / 6 | $692M |
| Apnimed, Inc. APMD | 45 | Elevated | Healthcare | United States | 4 / 6 | $691M |
| Lexicon Pharmaceuticals Inc LXRX | 54 | Elevated | Healthcare | United States | 5 / 6 | $690M |
| Cytek BioSciences Inc CTKB | 65 | Stretched | Healthcare | United States | 6 / 6 | $682M |
| OmniAb Inc OABI | 52 | Elevated | Healthcare | United States | 5 / 6 | $682M |
| 4D Molecular Therapeutics Inc FDMT | 61 | Stretched | Healthcare | United States | 5 / 6 | $679M |
| Genky DrugStores Co., Ltd. 9267.T | 43 | Elevated | Healthcare | Japan | 5 / 6 | $670M |
| Adlai Nortye Ltd ANL | 80 | Acute | Healthcare | Singapore | 4 / 6 | $668M |
| Biogena Good Vibes AG BIOG.VI | 53 | Elevated | Healthcare | Austria | 3 / 6 | $655M |
By sector
Industrials 3,117Technology 2,425Consumer Cyclical 2,231Healthcare 1,695Consumer Defensive 1,055Basic Materials 1,055Real Estate 1,011Communication Services 956Energy 487Utilities 343Financial Services 90
How the reading is built
Each company is scored on six mechanisms -- market expectation, operating pressure, cash conversion, leverage, concentration and competitive position -- from its own filed statements. A mechanism whose inputs do not clear its coverage floor is left unread rather than scored zero, and a reading built on thin coverage is pulled toward a neutral prior rather than claiming safety from what nobody looked at.
Descriptive, not advisory. These bands describe measured mechanisms; they are not investment advice, not a forecast, and not a statement about whether a share is worth owning.